On Jan. 12, 2023, Novo Nordisk announced the US Food and Drug Administration (FDA) approved a label update to permit first-line use of oral semaglutide (Rybelsus) in adult patients with type 2 diabetes (T2D).   New indication An FDA-granted label update for semaglutide, an oral glucagon-like peptide-1 (GLP-1) receptor agonist sold by Novo Nordisk under … Continue reading Rybelsus Wins FDA Label Update